Supernus Pharmaceuticals (SUPN) Revenue & Revenue Breakdown
Supernus Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$607.52M
Latest Revenue (Q)
$168.32M
Main Segment (Y)
Product
Supernus Pharmaceuticals Revenue by Period
Supernus Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $607.52M | -8.95% |
| 2022-12-31 | $667.24M | 15.09% |
| 2021-12-31 | $579.77M | 11.41% |
| 2020-12-31 | $520.40M | 32.50% |
| 2019-12-31 | $392.75M | -3.95% |
| 2018-12-31 | $408.90M | 35.29% |
| 2017-12-31 | $302.24M | 40.57% |
| 2016-12-31 | $215.00M | 48.87% |
| 2015-12-31 | $144.43M | 18.34% |
| 2014-12-31 | $122.05M | 915.43% |
| 2013-12-31 | $12.02M | 712.09% |
| 2012-12-31 | $1.48M | 84.31% |
| 2011-12-31 | $803.00K | 657.55% |
| 2010-12-31 | $106.00K | -99.72% |
| 2009-12-31 | $37.92M | 326.65% |
| 2008-12-31 | $8.89M | 109.97% |
| 2007-12-31 | $4.23M | - |
Supernus Pharmaceuticals generated $607.52M in revenue during NA 2023, up -8.95% compared to the previous quarter, and up 148.58% compared to the same period a year ago.
Supernus Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $168.32M | 17.18% |
| 2024-03-31 | $143.64M | -12.58% |
| 2023-12-31 | $164.31M | 6.78% |
| 2023-09-30 | $153.88M | 13.51% |
| 2023-06-30 | $135.56M | -11.84% |
| 2023-03-31 | $153.76M | -8.11% |
| 2022-12-31 | $167.33M | -5.65% |
| 2022-09-30 | $177.35M | 4.29% |
| 2022-06-30 | $170.05M | 11.50% |
| 2022-03-31 | $152.51M | -4.11% |
| 2021-12-31 | $159.05M | 7.13% |
| 2021-09-30 | $148.46M | 5.05% |
| 2021-06-30 | $141.33M | 7.94% |
| 2021-03-31 | $130.93M | -8.79% |
| 2020-12-31 | $143.56M | -7.46% |
| 2020-09-30 | $155.13M | 22.41% |
| 2020-06-30 | $126.73M | 33.43% |
| 2020-03-31 | $94.98M | -5.45% |
| 2019-12-31 | $100.45M | -1.66% |
| 2019-09-30 | $102.14M | -2.44% |
| 2019-06-30 | $104.69M | 22.49% |
| 2019-03-31 | $85.47M | -26.27% |
| 2018-12-31 | $115.93M | 12.56% |
| 2018-09-30 | $103.00M | 3.47% |
| 2018-06-30 | $99.54M | 10.07% |
| 2018-03-31 | $90.43M | 2.25% |
| 2017-12-31 | $88.44M | 10.00% |
| 2017-09-30 | $80.40M | 6.03% |
| 2017-06-30 | $75.83M | 31.70% |
| 2017-03-31 | $57.58M | -7.69% |
| 2016-12-31 | $62.37M | 9.79% |
| 2016-09-30 | $56.81M | 12.67% |
| 2016-06-30 | $50.42M | 17.05% |
| 2016-03-31 | $43.08M | 0.98% |
| 2015-12-31 | $42.66M | 10.55% |
| 2015-09-30 | $38.59M | 10.08% |
| 2015-06-30 | $35.05M | 24.59% |
| 2015-03-31 | $28.13M | -8.66% |
| 2014-12-31 | $30.80M | -41.32% |
| 2014-09-30 | $52.49M | 76.88% |
| 2014-06-30 | $29.68M | 226.78% |
| 2014-03-31 | $9.08M | -12.13% |
| 2013-12-31 | $10.34M | 722.20% |
| 2013-09-30 | $1.26M | 347.33% |
| 2013-06-30 | $281.00K | 91.16% |
| 2013-03-31 | $147.00K | -86.50% |
| 2012-12-31 | $1.09M | 1096.70% |
| 2012-09-30 | $91.00K | - |
| 2012-06-30 | $91.00K | -56.25% |
| 2012-03-31 | $208.00K | -102.11% |
| 2011-12-31 | $-9.85M | -89600.00% |
| 2011-09-30 | $11.00K | -98.53% |
| 2011-06-30 | $750.00K | 100.00% |
| 2011-03-31 | - | -100.00% |
| 2010-12-31 | $-8.63M | 67.83% |
| 2009-12-31 | $-5.14M | - |
Supernus Pharmaceuticals generated $168.32M in revenue during Q2 2024, up 17.18% compared to the previous quarter, and up 109.47% compared to the same period a year ago.
Supernus Pharmaceuticals Revenue Breakdown
Supernus Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Qelbree | $140.19M | $61.32M | $9.88M | - | - |
| Royalty | $33.59M | $17.81M | $12.27M | $11.05M | $9.36M |
| APOKYN | $75.08M | $75.31M | $99.23M | $74.30M | - |
| Trokendi Xr | $94.34M | $261.22M | $304.82M | $319.64M | $295.21M |
| GOCOVRI | $119.64M | $104.42M | $9.78M | - | - |
| Manufactured Product, Other | $31.28M | $31.82M | - | - | - |
| Oxtellar X R | $113.40M | $115.34M | $110.71M | $98.72M | $88.19M |
| Product | $573.93M | $649.43M | $567.50M | $509.35M | $383.40M |
| MYOBLOC | - | - | $19.51M | $9.75M | - |
| Osomolex ER | - | - | $188.00K | - | - |
| XADAGO | - | - | $13.39M | $6.94M | - |
| License | - | - | - | - | - |
Supernus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (48.58%), Qelbree (11.87%), GOCOVRI (10.13%), Oxtellar X R (9.60%), Trokendi Xr (7.98%), APOKYN (6.36%), Royalty (2.84%), and Manufactured Product, Other (2.65%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qelbree | $45.10M | $46.35M | $37.08M | $30.98M | $25.78M | $23.61M | $18.33M | $11.10M | $8.28M | $7.19M | $2.37M | $315.00K | - | - | - | - | - | - | - | - |
| Trokendi Xr | $15.99M | $19.60M | $20.63M | $19.32M | $34.79M | $57.19M | $69.60M | $71.60M | $62.83M | $73.29M | $80.94M | $78.78M | $71.82M | $78.51M | $82.91M | $89.67M | $75.22M | $77.33M | $78.96M | - |
| Royalty And License | $5.18M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| APOKYN | $16.65M | $18.76M | $21.51M | $17.61M | $17.21M | $18.15M | $18.26M | $20.45M | $18.45M | $25.89M | $24.63M | $26.98M | $21.73M | $31.21M | $34.48M | $8.60M | - | - | - | - |
| GOCOVRI | $26.56M | $31.99M | $32.89M | $28.75M | $26.01M | $29.24M | $27.88M | $24.70M | $22.60M | - | - | - | - | - | - | - | - | - | - | - |
| Manufactured Product, Other | $7.21M | $8.27M | $7.25M | $7.88M | $7.87M | $8.25M | $8.13M | $7.65M | $7.78M | - | - | - | - | - | - | - | - | - | - | - |
| Oxtellar X R | $26.94M | $31.05M | $29.64M | $23.80M | $28.91M | $27.34M | $30.53M | $29.96M | $27.52M | $28.59M | $29.73M | $25.02M | $27.37M | $22.74M | $28.36M | $23.68M | $23.94M | $22.68M | $22.70M | $23.39M |
| Product | $138.46M | $156.02M | $149.00M | $128.34M | $140.57M | $163.78M | $172.72M | $165.46M | $147.46M | $154.96M | $145.53M | $138.63M | $128.38M | $140.74M | $152.13M | $123.98M | $92.49M | $97.91M | $100.03M | $102.36M |
| Royalty | - | $8.30M | $4.88M | $7.23M | $13.19M | $3.54M | $4.63M | $4.59M | $5.04M | $4.09M | $2.93M | $2.70M | $2.55M | $2.81M | $3.00M | $2.75M | $2.49M | $2.54M | $2.11M | $2.34M |
| XADAGO | - | - | - | - | - | - | - | - | - | $4.00M | $3.28M | $2.89M | $3.22M | $3.81M | $2.33M | $801.00K | - | - | - | - |
| MYOBLOC | - | - | - | - | - | - | - | - | - | $6.04M | $4.60M | $4.64M | $4.24M | $4.47M | $4.05M | $1.23M | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Supernus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (49.08%), Qelbree (15.99%), Oxtellar X R (9.55%), GOCOVRI (9.42%), APOKYN (5.90%), Trokendi Xr (5.67%), Manufactured Product, Other (2.56%), and Royalty And License (1.84%).
Supernus Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| EVO | Evotec SE | $781.43M | $208.73M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| SUPN | Supernus Pharmaceuticals | $607.52M | $168.32M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| RGC | Regencell Bioscience | - | - |
SUPN Revenue FAQ
What is Supernus Pharmaceuticals’s yearly revenue?
Supernus Pharmaceuticals's yearly revenue for 2023 was $607.52M, representing a decrease of -8.95% compared to 2022. The company's yearly revenue for 2022 was $667.24M, representing an increase of 15.09% compared to 2021. SUPN's yearly revenue for 2021 was $579.78M, representing an increase of 11.41% compared to 2020.
What is Supernus Pharmaceuticals’s quarterly revenue?
Supernus Pharmaceuticals's quarterly revenue for Q2 2024 was $168.32M, a 17.18% increase from the previous quarter (Q1 2024), and a 24.17% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $143.64M, a -12.58% decrease from the previous quarter (Q4 2023), and a -6.58% decrease year-over-year (Q1 2023). SUPN's quarterly revenue for Q4 2023 was $164.31M, a 6.78% increase from the previous quarter (Q3 2023), and a -1.80% decrease year-over-year (Q4 2022).
What is Supernus Pharmaceuticals’s revenue growth rate?
Supernus Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 4.79%, and for the last 5 years (2019-2023) was 54.68%.
What are Supernus Pharmaceuticals’s revenue streams?
Supernus Pharmaceuticals's revenue streams in c 23 are Qelbree, Royalty, APOKYN, Trokendi Xr, GOCOVRI, Manufactured Product, Other, Oxtellar X R, and Product. Qelbree generated $140.19M in revenue, accounting 11.87% of the company's total revenue, up 128.62% year-over-year. Royalty generated $33.59M in revenue, accounting 2.84% of the company's total revenue, up 88.63% year-over-year. APOKYN generated $75.08M in revenue, accounting 6.36% of the company's total revenue, down -0.29% year-over-year. Trokendi Xr generated $94.34M in revenue, accounting 7.98% of the company's total revenue, down -63.89% year-over-year. GOCOVRI generated $119.64M in revenue, accounting 10.13% of the company's total revenue, up 14.57% year-over-year. Manufactured Product, Other generated $31.28M in revenue, accounting 2.65% of the company's total revenue, down -1.69% year-over-year. Oxtellar X R generated $113.4M in revenue, accounting 9.60% of the company's total revenue, down -1.68% year-over-year. Product generated $573.93M in revenue, accounting 48.58% of the company's total revenue, down -11.63% year-over-year.
What is Supernus Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Supernus Pharmaceuticals was Product. This segment made a revenue of $573.93M, representing 48.58% of the company's total revenue.